Skip to main content
Publications
Cheol Lee J, Hung JY, Kim YC, Chang GC, Soo Yoo S, Yang SH, Davis KL, Nagar SP, Taylor A, Yong Lee S, Shih JY. Real-world treatment patterns in patients with EGFR mutation-positive NSCLC receiving a first line, first- or second-generation EGFR tyrosine kinase inhibitor in South Korea and Taiwan. Asian Pac J Cancer Bio. 2021 May 20;6(2). doi: 10.31557/APJCB.2021.6.2.123-132
Martin-Richard M, Gallego R, Pericay C, Garcia Foncillas JG, Queralt B, Casado E, Barriuso J, Iranzo V, Juez I, Visa L, Saigi E, Barnadas A, Garcia-Albeniz X, Maurel J. Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study. Invest New Drugs. 2013 Dec;31(6):1573-9.